In short

Gaucher's disease type I is the most common form of this rare genetic disorder, affecting approximately 95% of cases in western countries and being the most prevalent Jewish genetic disorder. While it causes symptoms ranging from enlarged organs and bone pain to bleeding problems, effective treatments are available that can help patients live full, active lives well into old age.

What Is Gaucher's Disease Type I?

Gaucher's disease type I (pronounced go-SHAY) is a rare lysosomal storage disorder, a type of inherited condition that affects how the body breaks down certain fatty substances. It is the most common form of Gaucher disease, representing around 90% of all cases. Unlike types 2 and 3, type I is called non-neuropathic because it does not affect the brain or spinal cord.

People with Gaucher's disease type I don't have enough of an enzyme called glucocerebrosidase (also called GCase). This enzyme normally breaks down a fatty chemical in the body called glucocerebroside. When there isn't enough of this enzyme, glucocerebroside builds up inside cells called macrophages. These swollen cells, known as Gaucher cells, accumulate primarily in the spleen, liver, and bone marrow.

The disease is progressive, meaning symptoms can worsen over time if left untreated. However, the severity varies greatly from person to person. Some individuals have mild symptoms or even no symptoms at all, while others experience serious health problems.

10075697 E75.2 5C56.0Y C1961835

Non-cerebral juvenile Gaucher disease

Causes and Inheritance

Gaucher's disease type I is caused by changes (mutations) in the GBA gene, which is located on chromosome 1q21. This gene provides instructions for making the glucocerebrosidase enzyme. When the gene is mutated, the body cannot produce enough working enzyme. More than 450 different mutations in the GBA1 gene have been identified.

The disease follows an autosomal recessive inheritance pattern. This means a person must inherit two copies of the mutated gene—one from each parent—to develop the disease. Parents who each carry one copy of the mutated gene are called carriers. They typically do not show symptoms but can pass the gene to their children.

When both parents are carriers, there is a 25% (1 in 4) chance with each pregnancy that their child will have Gaucher disease, a 50% (1 in 2) chance the child will be a carrier, and a 25% (1 in 4) chance the child will be unaffected.

Who Is Affected

Gaucher's disease type I affects approximately 1 to 9 in 100,000 people in the general population. In the United States, about 6,000 people have the disorder, with roughly 95% having type I.

The disease is much more common among people of Ashkenazi Jewish (Eastern and Central European Jewish) descent. In this population, Gaucher's disease type I affects approximately 1 in 600 individuals, making it the most common Jewish genetic disorder. About 1 in 17 people within the Ashkenazi Jewish community are carriers of the mutated gene.

Both males and females share an equal risk of being affected by the disease.

Signs and Symptoms

Although Gaucher's disease type I can be diagnosed at any age, half of patients are under the age of 20 at diagnosis. Symptoms most often appear in childhood or teenage years, but they can begin at any age, including late adulthood. The clinical presentation is highly variable, with some people having mild symptoms while others experience severe complications.

Organ Enlargement

One of the most common features of Gaucher's disease type I is the enlargement of organs. The spleen becomes greatly enlarged (splenomegaly) in about 90% of cases, and the liver also becomes enlarged (hepatomegaly) in 80% of cases. This enlargement can cause a painful, swollen belly and may interfere with eating a complete meal. In rare cases, liver enlargement can progress to fibrosis and cirrhosis.

Blood Problems

Gaucher cells that accumulate in the bone marrow and spleen interfere with the normal production of blood cells, leading to several blood-related problems:

Anemia (low red blood cell count) causes fatigue and shortness of breath
Thrombocytopenia (low platelet count) leads to easy bruising and bleeding problems
Less commonly, leukopenia (low white blood cell count) may occur

Bleeding Issues

Low platelet counts prevent normal blood clotting. Patients may experience frequent nosebleeds, gum bleeding, or prolonged bleeding after dental work or surgery. Sometimes more serious bleeding can occur in the gastrointestinal tract, urinary system, or after delivering a baby.

Bone Problems

Bone abnormalities are present in 80% of cases. These can include:

Severe bone pain, which can be intense
Osteopenia (reduced bone density) that can lead to pathological fractures
Bone deformities
Bone infarctions (areas of dead bone tissue due to lack of blood supply)
Aseptic osteonecrosis (bone death without infection)
Vertebral compression

Without treatment, damage to bones can be permanent.

Other Symptoms

Additional symptoms may include growth retardation or delayed puberty in children, frequent feelings of tiredness (asthenia), and less commonly, involvement of the lungs, kidneys, or heart. Sometimes the skin develops brown, pigmented spots.

Spleen
Liver
Bone marrow
Bones
Blood

Diagnosis and Testing

Diagnosing Gaucher's disease type I involves several steps. A complete examination typically includes questions about symptoms and family medical history, physical examination to check organ size, and specialized tests.

Blood Tests

The primary diagnostic test involves blood samples to measure the activity of the glucocerebrosidase enzyme. A significant reduction in enzyme activity confirms the diagnosis. Genetic testing can also identify mutations in the GBA gene.

Blood tests may also reveal certain biological markers that are elevated in Gaucher disease, including chitotriosidase, angiotensin converting enzyme, ferritin, and tartrate-resistant acid phosphatases. These markers are important both for initial diagnosis and for monitoring the disease over time.

Imaging Tests

Various imaging studies help assess the extent of organ involvement and bone damage:

Ultrasound or MRI scans to evaluate liver and spleen enlargement
X-rays to assess bone disease
Bone density scans (osteodensitometry) to evaluate osteopenia of the lumbar spine and femoral neck
Bone scintigraphy to detect bone lesions and complications
Cardiac ultrasound to check for pulmonary arterial hypertension

Genetic Counseling

Genetic counseling is recommended for individuals with Gaucher disease and their families. Carrier testing can identify family members who carry one copy of the mutated gene. Prenatal screening is available for pregnant women to test for the disease in the developing baby.

In rare cases, genotyping may provide prognostic information. For example, patients with a specific mutation called homozygous N370S will not develop neurological disease.

Treatment Options

Treatment for Gaucher's disease type I is critical for minimizing symptoms and preventing lasting damage to the body. There are two main types of therapy approved by the U.S. Food and Drug Administration: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).

Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy works by providing the body with a manufactured version of the missing glucocerebrosidase enzyme. This allows the body to break down the accumulated glucocerebroside.

ERT is delivered through intravenous (IV) infusion, typically once every two weeks. Patients can receive infusions at an infusion center, a hospital-based treatment center, or at home with the help of a home health nurse.

Three ERT medications are currently approved for Gaucher's disease type I:

Cerezyme® (imiglucerase)
VPRIV® (velaglucerase alfa)
Elelyso® (taliglucerase alfa)

ERT is highly effective in reversing the visceral (organ) and blood-related problems of Gaucher disease. The therapy has a remarkable effect on liver and spleen enlargement, with an average overall decrease of 25% in organ volume after 6 months of treatment. In most patients with anemia, hemoglobin levels rise by 1.5 g/dL during the first 4-6 months of therapy.

However, skeletal disease responds more slowly to treatment, and lung involvement is relatively resistant to ERT.

Substrate Reduction Therapy (SRT)

Substrate reduction therapy works differently from ERT. Instead of replacing the missing enzyme, SRT reduces the amount of glucocerebroside that the body produces. This decreases the work the body's enzyme must do.

SRT medications are taken orally (by mouth). Two drugs are currently approved for Gaucher's disease type I:

Cerdelga® (eliglustat)
Zavesca® (miglustat)

SRTs are not available for all patients. They are not approved for use in people under 18 years old or in women who are breastfeeding, pregnant, or trying to become pregnant. Eligibility also depends on genetic testing to determine how the body processes the medication.

Supportive Treatments

In addition to the main therapies, patients may need supportive treatments to manage specific symptoms:

Pain medication for bone pain
Physical therapy to maintain mobility and strengthen bones
Nutritional supplements if deficiencies are identified
In some cases, orthopedic surgery for severe bone complications

Outlook and Quality of Life

The outlook for people with Gaucher's disease type I has improved dramatically with available treatments. Because enzyme deficiency varies from person to person, symptoms can differ greatly. Some patients with mild disease can apparently go untreated without disease progression, although identifying such patients remains challenging.

With proper treatment and management, patients can live well into old age with excellent quality of life. While untreated patients generally survive to adulthood, the clinical course and life expectancy are variable.

Early recognition, diagnosis, and treatment are key for the best possible outcomes. An early clinical presentation predicts a more severe disease course, highlighting the importance of recognizing the disease as soon as possible to ensure earlier intervention. With proper treatment and management, patients can lower their risk of developing permanent damage.

The most important factor in maintaining optimal health is seeing a Gaucher specialist regularly. Most general practitioners have no experience with Gaucher disease, and without proper management, irreversible damage can occur. For many patients, seeing a specialist requires only one visit per year.

Managing Daily Life

Living with Gaucher's disease type I involves more than just taking medication. Several lifestyle strategies can help manage symptoms and maintain health.

Sticking to Your Treatment Plan

The most important aspect of managing Gaucher disease is adhering to the treatment plan prescribed by your doctor. Setting medication and appointment reminders on your phone or calendar can help you stay on track. Keeping a symptom journal to share with your doctor allows them to better assess whether your treatment is working.

Managing Fatigue

Fatigue is common in Gaucher disease due to anemia and other symptoms. To conserve energy:

Schedule breaks throughout the day
Break large tasks into smaller, manageable units
Work on challenging tasks when you feel most rested
Delegate physically demanding chores when possible
Don't hesitate to cancel social commitments when tired

Exercise and Bone Health

Physical activity is one of the best ways to support bone health, but you should consult your doctor and physical therapist before starting an exercise program. Low-impact activities that may be suggested include walking, swimming, strength training, stretching, yoga, and tai chi. People with Gaucher disease have a higher risk of fractures, so intense, high-impact exercises should be avoided.

Diet and Nutrition

If Gaucher disease causes an enlarged spleen or liver, it can put pressure on your stomach, making you feel full after just a few bites. Even if you aren't hungry, eating nutritious meals is important for staying healthy. Your diet should have the right balance of calories and nutrients, with plenty of calcium and vitamin D to keep bones strong.

Monitoring Your Health

Regular assessments are important for monitoring Gaucher disease. Specialists track health indicators such as spleen and liver volume, bone density, and blood counts. This monitoring is critical for tailoring treatment dosage and avoiding complications.

Emotional Support

Living with a chronic condition can be emotionally challenging. Reaching out to a network of family and friends provides important emotional support. Connecting with others who also have Gaucher disease can be especially valuable, as they truly understand what you're going through. Some patients find stress-reduction techniques like yoga or meditation helpful.